Is Huntington’s Disease More Common in Males or Females?

Huntington’s disease affects men and women with equal genetic probability, since the responsible gene sits on chromosome 4, not on a sex chromosome. Yet the two sexes experience the disease differently in almost every measurable way, from when symptoms first appear to how quickly they worsen. In the United States, women are actually diagnosed slightly more often than men, and emerging research points to meaningful sex-based differences in progression, psychiatric profile, and even how the underlying mutation behaves when passed from parent to child.

Diagnostic Frequency and Survival

Because Huntington’s disease follows an autosomal dominant inheritance pattern, a child of an affected parent has a fifty-fifty chance of inheriting the mutation regardless of whether the child is male or female. Population-level data, however, show a small but consistent skew in who ends up with a formal diagnosis. A large U.S. study using insurance claims found that the age-adjusted diagnostic frequency was about 7.05 per 100,000 in women compared to 6.10 per 100,000 in men.¹ That gap is real but modest. It may partly reflect differences in healthcare-seeking behavior rather than a true biological excess in women: women in many populations engage with the medical system more frequently, and as we will see later, they are also more likely to pursue predictive genetic testing.

When it comes to dying from the disease, the sexes are on nearly identical footing. A U.S. mortality analysis found comparable age-adjusted mortality rates for men and women, roughly 5.2 versus 5.0 per million.² A Norwegian study spanning three decades reported no significant sex difference in age at death, with mean ages in the low-to-mid sixties for both groups.³ So while the journey through the disease looks different for men and women, the destination, measured in lifespan, is largely the same.

When Symptoms First Appear

One of the clearest sex differences in Huntington’s disease is the age at which motor symptoms begin. A 2024 analysis of over a thousand patients found that women, on average, developed symptoms later than men. The difference was most pronounced in patients carrying a relatively short version of the expanded CAG repeat, the stretch of genetic code whose length largely determines onset timing. In that subgroup, women’s later onset was striking and consistent.⁴ The pattern held across the broader population too, though it was less dramatic at the extreme end of repeat lengths where onset is early and severe regardless of sex.

The picture gets more complex when other genetic factors enter the frame. One study found that a specific variant of the APOE gene, the same gene famous for its role in Alzheimer’s risk, was linked to significantly earlier onset in men than in women.⁵ That sex-specific effect was not seen with other APOE variants, suggesting that at least some modifier genes interact with biological sex to shift the disease’s timeline in one direction or the other.

How Fathers and Mothers Pass the Mutation Differently

Huntington’s disease is caused by an abnormally long CAG repeat in the huntingtin gene, and the number of repeats is not always stable from one generation to the next. It can expand or contract when a parent passes the gene to a child, and the direction of that change depends heavily on whether the affected parent is the father or the mother.

Fathers tend to transmit expanded repeats. On average, the CAG count grows by about 1.7 repeats in paternal transmission, and large expansions of more than seven repeats happen almost exclusively through fathers.⁶ Mothers, by contrast, tend to pass on the same repeat length or a slightly shorter one. Maternal transmissions are significantly more likely to show no change or a contraction than paternal ones.⁷ The reason lies in the biology of sperm and egg production: the processes of cell division in male germ cells appear to favor repeat expansion, while female germ cells are more stable.

This asymmetry has a direct clinical consequence. Since longer repeats mean earlier, more severe disease, children who inherit the mutation from an affected father are at greater risk for a dramatically younger onset. Juvenile Huntington’s disease, which strikes before age twenty and tends to involve rigidity and intellectual decline rather than the classic chorea, is overwhelmingly associated with paternal inheritance.⁸

An unexpected wrinkle emerged from a study of a large Venezuelan pedigree: in maternal transmissions, the repeat-length change also depended on the sex of the child. Sons of affected mothers tended to receive expanded repeats, while daughters tended to receive contracted ones.⁹ If that finding holds across other populations, it means the offspring’s own biology may influence how the mutation behaves during transmission, adding another layer to the genetics.

Women May Progress Faster Once Symptoms Begin

Here is where the sex story in Huntington’s disease becomes counterintuitive. Women tend to get a slightly later start, but once symptoms appear, they seem to lose ground more quickly. A large European cohort study found that women with mid-age onset showed worse scores than men in motor function, day-to-day independence, and overall functional capacity, and that these gaps widened over time. Women also showed a faster rate of progression on motor, functional, and independence measures.¹⁰

More recent data reinforce that pattern. A 2025 study measuring how clinical decline tracks with cumulative disease burden found that women showed steeper declines in motor scores, cognitive test performance, and functional capacity than men at the same burden level.¹¹ This is a consistent finding that has emerged across multiple research groups, and it raises the question of why women’s neurons seem more vulnerable to damage once the disease process is underway, despite the later start.

One clue comes from cerebrospinal fluid biomarkers. Neurofilament light chain, a protein released when neurons are damaged, correlates more tightly with clinical severity in women than in men. In one study, the correlation between this biomarker and a composite clinical score was strong in women but only moderate in men, even though the raw biomarker levels were similar between the sexes.¹² That suggests the same degree of neuronal damage may translate into greater functional impairment in women, though the reasons remain unclear.

Psychiatric Symptoms and the Depression Gap

Depression is common in Huntington’s disease regardless of sex, but several studies have found that women carry a heavier psychiatric burden. Both current and lifetime depression are reported more frequently in women with the disease, while men are more likely to report histories of alcohol misuse and smoking.¹³¹⁴

Whether this sex difference is specific to Huntington’s or just mirrors the general population, where depression is also more commonly diagnosed in women, is hard to untangle. A European population study designed to answer that question found that disease stage was the strongest predictor of depressive symptoms and general psychological distress, while sex was not a significant predictor after accounting for stage. Neither disease stage nor sex predicted anxiety levels.¹⁵ In other words, how far the disease has advanced matters more than whether the patient is male or female. The higher rate of depression seen in women with Huntington’s may simply reflect higher rates of depression in women generally, rather than something unique to how the disease attacks the brain.

Estrogen and the Biology Behind Sex Differences

The fact that women develop symptoms later but then decline faster once symptoms emerge has pushed researchers toward sex hormones as a possible explanation. Estrogen, specifically the form called 17β-estradiol, has well-documented neuroprotective effects in the brain. In a rat model of Huntington’s disease, male animals lost far more of the specific neurons targeted by the disease, the medium spiny neurons in the striatum, than females did. The number of surviving neurons tracked closely with 17β-estradiol levels, and those neurons expressed estrogen receptors, suggesting a direct protective mechanism.¹⁶

The molecular picture adds detail. In cell culture experiments, 17β-estradiol normally triggers the huntingtin protein and another protective protein called neuroglobin to join forces and relocate to mitochondria, where they shield the cell from programmed death. But when the huntingtin protein carries the abnormal expansion that causes the disease, this entire protective pathway breaks down. The mutant protein can no longer respond to estrogen’s signal, effectively disabling a key survival mechanism.¹⁷ That helps explain a paradox: estrogen may delay onset in women by providing some early neuroprotection, but once the disease reaches a certain threshold of severity, the mutant protein overwhelms that protective capacity and the advantage erodes.

Supporting evidence comes from an unexpected angle. A study of genetic modifiers found that certain variants in glutamate receptor genes had a significant effect on age of onset in women but not in men. When the researchers stratified their results by estimated menopausal status, the female-specific findings were concentrated in premenopausal women, implicating active hormonal signaling as the mediating factor.¹⁸ Combined with the estrogen data, this paints a picture in which female sex hormones buy time early in the disease process but do not fundamentally alter its trajectory.

Genetic Modifiers That Work Differently by Sex

The CAG repeat length in the huntingtin gene accounts for the largest share of variation in when symptoms start, but it does not explain everything. Modifier genes fill part of the gap, and some of these modifiers behave differently in men and women. The glutamate receptor variants described above are one example, adding roughly seven percent of additional variance in onset for women specifically.¹⁸

Men have their own sex-specific modifier. A variant in a gene called PGC-1α, which plays a role in mitochondrial energy production, was linked to earlier motor onset in men carrying the Huntington mutation but had no effect on onset in women.¹⁹ This means two people with the same CAG repeat length could develop symptoms years apart depending on their sex and which modifier variants they carry. It also means that future treatments targeting these pathways may need to be tailored differently for men and women.

What Animal Models Show

Mouse models of Huntington’s disease have turned out to be surprisingly useful for confirming and dissecting sex differences. In one knock-in model, female mice showed distinct behavioral abnormalities that were not present in males or in healthy mice of either sex, including excessive grooming and altered running behavior. Male mice, on the other hand, showed a pronounced drop in striatal ascorbate, an antioxidant, during behavioral testing, a change not observed in females. This suggests that the two sexes may experience different neuropathological changes even when carrying the same mutation.²⁰

In another widely used model, male mice displayed earlier and more severe learning deficits, impaired paw coordination, and reduced electrical activity in striatal neurons, while female mice were relatively spared on those measures.²¹ A third model showed the opposite pattern: female mice had worse spontaneous locomotion and motor coordination than males, echoing the faster functional decline seen in human women.²² The inconsistency across models is actually informative: it suggests that the specific CAG repeat length, genetic background, and stage of disease all interact with sex to produce different profiles. No single model captures the full picture, which is exactly what the human data show too.

Brain imaging in mice adds structural evidence. In the R6/1 model, male mice showed significant regional brain shrinkage by seventeen weeks, with visible expansion of the ventricles and specific patterns of tissue loss. Female mice at the same age showed overall volume reduction but no detectable regional differences, suggesting that their brains deteriorated more uniformly and perhaps more slowly.²³

Who Seeks Predictive Testing

One area where the sex difference is stark and consistent has nothing to do with biology: women are more likely than men to seek predictive genetic testing for Huntington’s disease. A report covering twenty-two years of predictive testing in the United Kingdom found that about 56% of people who came for testing were women and 44% were men.²⁴ This gap is not unique to Huntington’s; women consistently use predictive genetic testing and health services at higher rates across a range of conditions.²⁵

The testing imbalance may feed back into the diagnostic frequency data. If women at risk for Huntington’s are more likely to get tested, they are also more likely to receive a formal diagnosis earlier, before severe symptoms would have brought them to medical attention anyway. That alone could account for some of the gap between male and female diagnostic rates described at the top of this article. It is a reminder that when disease frequency numbers differ by sex, the explanation is not always biological. Sometimes it is about who walks through the clinic door.

For families weighing the decision to pursue testing, the sex-specific findings described throughout this article add nuance. A woman who tests positive faces the likelihood of somewhat later onset but potentially faster deterioration once symptoms arrive. A man who inherits the mutation from his father may be at elevated risk for a large repeat expansion and earlier onset. These are population-level tendencies, not guarantees for any individual, but they are the kind of information that genetic counselors increasingly factor into their conversations with families.